{"nctId":"NCT00413244","briefTitle":"The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery","startDateStruct":{"date":"2007-01"},"conditions":["Coronary Artery Disease"],"count":51,"armGroups":[{"label":"Androgel treatment","type":"EXPERIMENTAL","interventionNames":["Drug: AndroGel 5 Grams"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"AndroGel 5 Grams","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male patients with coronary artery disease (CAD) (one to three vessel diseased).\n* Stable cardiac status at least 3 months after percutaneous coronary intervention (PCI).\n* No change in cardiac medications for 4 weeks prior to enrollment.\n* Testosterone \\< 300 ng/dl or free testosterone \\< 5.0 ng/dl or bioavailable testosterone \\< 150 ng/dl.\n* Sex Hormone Binding Globulin (SHBG) \\< 7nmol/liter and Free Testosterone \\< 50pg/dl\n* Prostate Specific Antigen (PSA) \\< 2.5 ng/mL or 2.6-3.7ng/mL with a negative prostate biopsy within the last 6 months and pathology report available for investigator's review.\n* Subgroup of diabetics with well to moderately controlled diabetes (defined by a HgbA1c of \\< 9mg/dL.\n\nExclusion Criteria:\n\n* Hematocrit greater than 50%.\n* Severe hypertension (exhibit systolic blood pressure \\>180mmHg and diastolic blood pressure \\>110 mmHg at baseline visit or a have a history of malignant hypertension.\n* Significant cardiac arrhythmia (supraventricular tachycardia \\[SVT\\] or ventricular tachycardia with heart rate exceeding 110 beats per minute at Visit 1).\n* ECG abnormalities precluding ST segment analysis on treadmill, or inability to walk on treadmill.\n* Poorly controlled, symptomatic, active medical problems (HIV, hepatitis, cancer, benign prostatic hypertrophy, alcohol or drug abuse, major depressive disorder).\n* Neurological or psychiatric disorder that would compromise the patient's ability to give informed consent or adhere to the requirements of the protocol.\n* History of prostate cancer\n* History of hypersensitivity to transdermal testosterone gel.\n* International Prostate Symptom Score (IPSS) \\>19 at Visit 1.","healthyVolunteers":false,"sex":"MALE","minimumAge":"40 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cardiac Stress Test: Time to ST Depression","description":"Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"439.1","spread":"205.2"},{"groupId":"OG001","value":"279.5","spread":"130.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"364.0","spread":"141.4"},{"groupId":"OG001","value":"292.6","spread":"63.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"433.0","spread":"123.2"},{"groupId":"OG001","value":"342.2","spread":"62.7"}]}]}]},{"type":"PRIMARY","title":"Cardiac Stress Testing: Exercise Capacity","description":"Exercise capacity was measured using exercise time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"589.7","spread":"114.6"},{"groupId":"OG001","value":"452.4","spread":"122.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"607.6","spread":"152.0"},{"groupId":"OG001","value":"472.1","spread":"98.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"614.0","spread":"115.4"},{"groupId":"OG001","value":"470.0","spread":"143.8"}]}]}]},{"type":"SECONDARY","title":"Seattle Angina Questionnaire (SAQ)","description":"A cardiac disease-related quality-of-life measure. The SAQ is a self-report instrument with 19 items that, yields five subscale scores: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.\n\nData not collected.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Reactive Hyperemia Index","description":"The Reactive Hyperemia Index measures the endothelial function and predicts future coronary events. In general RHI values below 2 are categorized as endothelial dysfunction and have a greater plaque burden, whereas higher RHI values are considered normal or improved endothelial function. PAT is the technique to non-invasively assess endothelial function. It comprises finger probes to evaluate digital volume changes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":"0.72"},{"groupId":"OG001","value":"1.85","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"0.49"},{"groupId":"OG001","value":"1.81","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":"0.49"},{"groupId":"OG001","value":"1.77","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"0.58"},{"groupId":"OG001","value":"1.74","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"International Prostate Symptom Score (IPSS)","description":"IPSS has 7 questions related to symptoms, each item scored 1-5. Total score can range from 0 to 35 (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 (\"delighted\" to \"terrible\".) Data not collected.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Metabolic Equivalents of Task (METS)","description":"The Metabolic Equivalent of Task (MET), or simply metabolic equivalent, is a physiological measure expressing the energy cost of physical activities and is defined as the ratio of metabolic rate (and therefore the rate of energy consumption) during a specific physical activity to a reference metabolic rate, set by convention to 3.5 ml O2·kg-1·min-1 or equivalently","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":"2.2"},{"groupId":"OG001","value":"9.0","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"2.2"},{"groupId":"OG001","value":"9.0","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"3.0"},{"groupId":"OG001","value":"9.2","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"2.2"},{"groupId":"OG001","value":"9.4","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Aging Male Symptoms (AMS)","description":"The scale assesses symptoms of aging and their impact on HRQoL in males, and increases with increasing severity (1 to 5) of subjectively perceived complaints in 17 items. Scale ranges from 17-85 (no symptoms to extremely severe symptoms.)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":"11.4"},{"groupId":"OG001","value":"35.8","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":"10.1"},{"groupId":"OG001","value":"29.8","spread":"11.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":"11.4"},{"groupId":"OG001","value":"35.9","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":"8.5"},{"groupId":"OG001","value":"31.4","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"International Index of Erectile Function (IIEF)","description":"Questions 1-5 15 of the IIEF relates to erectile function scale 0 - 30 (severe erectile dysfunction to no erectile dysfunction).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"8.7"},{"groupId":"OG001","value":"12.2","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":"9.0"},{"groupId":"OG001","value":"10.1","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"9.6"},{"groupId":"OG001","value":"14.2","spread":"10.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":"10.0"},{"groupId":"OG001","value":"12.5","spread":"9.7"}]}]}]},{"type":"SECONDARY","title":"IIEF-II Orgasmic Function","description":"Questions 9-10 of the IIEF relates to orgasmic function scale 0 - 10 (from no impairment to severe impairment)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"3.3"},{"groupId":"OG001","value":"4.4","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"3.5"},{"groupId":"OG001","value":"4.2","spread":"4.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"3.7"},{"groupId":"OG001","value":"5.8","spread":"4.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"3.4"},{"groupId":"OG001","value":"5.5","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"IIEF -III: Sexual Desire","description":"Questions 11-12 of the IIEF relates to sexual desire scale 0-10 (from very low to very high)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"2.1"},{"groupId":"OG001","value":"5.4","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"2.7"},{"groupId":"OG001","value":"4.8","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"2.3"},{"groupId":"OG001","value":"5.6","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"2.4"},{"groupId":"OG001","value":"5.5","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"IIEF-IV: Intercourse Satisfaction","description":"Questions 6,7, 8 of the IIEF relates to intercourse satisfaction scale 0 - 15 (from very dissatisfied to very satisfied)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"4.0"},{"groupId":"OG001","value":"5.0","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"4.6"},{"groupId":"OG001","value":"3.6","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"4.9"},{"groupId":"OG001","value":"6.0","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"5.1"},{"groupId":"OG001","value":"5.2","spread":"5.1"}]}]}]},{"type":"SECONDARY","title":"IIEF-V: Over-all Satisfaction","description":"Questions 13,14 of the IIEF relates to specifically to overall satisfaction scale from 0 - 10 (very dissatisfied to very satisfied)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"2.5"},{"groupId":"OG001","value":"4.3","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"2.9"},{"groupId":"OG001","value":"3.8","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"2.9"},{"groupId":"OG001","value":"5.2","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"3.0"},{"groupId":"OG001","value":"4.9","spread":"3.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":[]}}}